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Abstract
Introduction: Epithelial to mesenchymal transition (EMT) is associated with the basal-like breast cancer
phenotypes. Sixty percent of basal-like cancers have been shown to express wild-type estrogen receptor beta
(ERb1). However, it is still unclear whether the ERb expression is related to EMT, invasion and metastasis in breast
cancer. In the present study, we examined whether ERb1 through regulating EMT can influence invasion and
metastasis in basal-like cancers.
Methods: Basal-like breast cancer cells (MDA-MB-231 and Hs578T), in which ERb1 was either overexpressed or
down-regulated were analyzed for their ability to migrate and invade (wound-healing assay, matrigel-coated
Transwell assay) as well as for the expression of EMT markers and components of the EGFR pathway
(immunoblotting, RT-PCR). Co-immunoprecipitation and ubiquitylation assays were employed to examine whether
ERb1 alters epidermal growth factor receptor (EGFR) protein degradation and the interaction between EGFR and
the ubiquitin ligase c-Cbl. The metastatic potential of the ERb1-expressing MDA-MB-231 cells was evaluated in vivo
in a zebrafish xenotransplantation model and the correlation between ERb1 and E-cadherin expression was
examined in 208 clinical breast cancer specimens by immunohistochemistry.
Results: Here we show that ERb1 inhibits EMT and invasion in basal-like breast cancer cells when they grow either
in vitro or in vivo in zebrafish. The inhibition of EMT correlates with an ERb1-mediated up-regulation of miR-200a/b/
429 and the subsequent repression of ZEB1 and SIP1, which results in increased expression of E-cadherin. The
positive correlation of ERb1 and E-cadherin expression was additionally observed in breast tumor samples. Down-
regulation of the basal marker EGFR through stabilization of the ubiquitin ligase c-Cbl complexes and subsequent
ubiquitylation and degradation of the activated receptor is involved in the ERb1-mediated repression of EMT and
induction of EGFR signaling abolished the ability of ERb1 to sustain the epithelial phenotype.
Conclusions: Taken together, the results of our study strengthen the association of ERb1 with the regulation of
EMT and propose the receptor as a potential crucial marker in predicting metastasis in breast cancer.
Introduction
In the last decade, genomic studies have identified five
breast cancer intrinsic subtypes (Luminal A, Luminal B,
HER2 (overexpressing the ERBB2), basal-like and clau-
din-low) [1,2]. In a recent study, an integrated analysis
of copy number and gene expression split the intrinsic
subtypes revealing novel subgroups with distinct clinical
outcome, including a high-risk ERa-positive subgroup
and a subset of ERa-positive and ERa-negative cases
with a favorable outcome. According to this analysis,
the majority of the basal-like tumors formed a high-
genomic instability subgroup with relatively good long-
term outcomes (after five years) [3]. Basal-like pheno-
types represent tumors that express markers that are
characteristic of the myoepithelium of the normal mam-
mary gland, such as epidermal growth factor receptor
(EGFR), p63 and the basal cytokeratins CK14, CK5/6
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and CK17 [1,4]. They show partial overlap with the tri-
ple-negative breast cancers that are characterized by a
lack of HER2 gene amplification and estrogen and pro-
gesterone receptor expression. Approximately 75% of
triple-negative breast cancers are classified as basal-like
tumors on the basis of their overall gene-expression pro-
file. The basal-like phenotype represents a more homoge-
neous group of cancers than the group of cancers defined
by triple negativity [5]. Basal-like tumors are often resis-
tant to chemotherapy and develop distant metastases in
characteristic tissues, such as lung and brain [6]. Recent
studies have suggested a correlation between the basal
phenotypes and epithelial to mesenchymal transition
(EMT) [7].
EMT has been reported to promote invasion during the
progression of breast carcinomas and it is considered as
an essential early step in tumor metastasis [8,9]. EMT is
characterized by loss of cellular adhesion, which is
mediated by down-regulation of adhesion molecules,
such as CD44 and E-cadherin [10,11]. The expression of
E-cadherin is regulated by a number of transcriptional
repressors, which include SNAIL, SLUG, SIP-1 (ZEB-2),
δEF1 (ZEB-1) and TWIST [12-15]. The family of micro-
RNAs 200 (miR-200a, miR-200b, miR-200c, miR-141 and
miR-429) and the miR-205A regulate the expression of
the transcriptional repressors of E-cadherin ZEB-1 and
ZEB-2 and, consequently, the levels of E-cadherin in
breast cancer cells and tissues. A decrease in the expres-
sion of these microRNAs has been observed in cells that
have undergone EMT and in mesenchymal regions of
metaplastic breast cancer lacking E-cadherin expression
[16]. Up-regulation of components of the EGFR signaling
pathway, such as ERK2, has also been reported to influ-
ence the levels of E-cadherin by regulating the transcrip-
tional repressors ZEB-1 and ZEB-2 [17,18].
The potential role of estrogen receptors in regulating
EMT and aggressive behavior in breast cancer has recently
been under investigation [19]. Although a decline of ERa
levels is detected in invasive breast cancers, a few studies
have shown regulation of cell migration and invasion by
ERa [20,21]. Recent studies have also associated the ERb
isoforms ERb1, ERb2 and ERb5 with the regulation of cell
migration and invasion in prostate cancer [22,23]. Down-
regulation of the fully functional ERb isoform ERb1 (also
known as wild-type ERb) promoted EMT in prostate cancer
cells and this correlated with the loss of ERb1 in high Glea-
son grade invasive prostate carcinoma [22]. Interestingly,
patients with triple-negative breast cancer that were treated
with adjuvant tamoxifen have been shown to have signifi-
cantly better survival when the tumors were positive for
ERb1 [24]. In addition, clinical findings showed an inverse
correlation between ERb1 positivity and expression of
EGFR, a crucial component in basal-like cancers that drives
proliferation and EMT [25]. Given that down-regulation of
ERb1 has been observed in invasive breast cancers, in this
study we hypothesized that ERb1 functions to maintain an
epithelial phenotype in breast cancer and examined whether
ERb1 reduces the invasiveness of basal cancer cells by
repressing EMT [26].
Materials and methods
Cells, reagents and transfections
The breast cancer cell lines (MDA-MB-231, Hs578T and
MCF-7) and the lung cancer cell line (H1299) were
obtained from the ATCC. In 17b-estradiol (E2) experi-
ments, cells were maintained in phenol red-free media con-
taining two or five percent dextran-coated charcoal (DCC)-
treated fetal calf serum (FCS). Transforming growth factor
b (TGF-b) and EGF experiments were performed in
serum-free or 0.5% FCS media with recombinant human
TGF-b1 (5 ng/ml; R & D Systems, Minneapolis, MN USA)
for one to three days or EGF (10 ng/ml; Sigma) for 24 h.
MDA-MB-231 and Hs578T cells were infected with lenti-
viruses containing the plenti6/V5 empty vector or the
recombinant pLenti6/V5-D-FLAG-ERb1 and pLenti6/V5-
D-FLAG-ERa plasmids as described previously [27]. Cells
were transfected twice with ERb-specific siRNAs (Invitro-
gen, Carlsbad, CA USA), target sequences 1# 5’-TTAGC-
GACGTCTGTCGCGTCTTCAC-3’; 2# 5’-TTACGAC
ATTAAGTAGTGTCGTCCC-3’; 3# 5’-TATTGACCGC-
TACCTGGTGATTTCC-3’. siRNA targeting luciferase was
used as a control (Cat. No. 12935-146, Invitrogen). For the
expression of wild-type EGFR, cells were stably transfected
with the pBABE-EGFR construct (Addgene, plasmid #
11011, Cambridge, MA USA), using the empty pBABE vec-
tor (Addgene, plasmid # 1764) as a control. Cells were
transfected with microRNA inhibitors at a final concentra-
tion of 300 nM (100 nM of each of miR-200a, miR-200b
and miR-429 2’-O-Methylmodified oligonucleotides, Dhar-
macon, Waltham, MA USA) or a negative control inhibitor
(300 nM). The complementary sequences for miR-200a,
miR-200b and miR-429 were cloned in the 3’ end of the
luciferace gene into the PGL3-promoter vector (Promega,
San Luis Obispo, CA USA). A total of 2 × 105 cells were
seeded at 24-well plates and transfected with 800 ng DNA/
well (PGL3, b-gal) as well as microRNA inhibitors.
Twenty-four hours after transfection, cells were lysed and
analyzed using a Luciferase Assay (Promega). Luciferase
units were normalized to b-galactosidase units. For ERE-
luciferase reporter assays, cells were incubated in DCC-
FCS media for 48 h and transfected with 800 ng DNA/well
(3-ERE-TATA-LUC reporter plasmid, b-gal plasmid) using
LipofectamineTM 2000 (Invitrogen). Cells were mock trea-
ted (EtOH) or treated with E2 for 24 h in 2% DCC-FCS
media. Reporter gene activity was normalized to b-galacto-
sidase enzyme activity.
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Migration and invasion assays
In the wound-healing assay, cells were allowed to form
monolayers at 24-well plates. The monolayer was
scratched with a pipette tip to form the wound. Twelve
hours later, images of the wound were taken using a 10×
objective in an OLYMPUS IX51 microscope equipped
with an OLYMPUS camera (OLYMPUS, Center Valley,
PA USA) and cells in the wound area in five independent
fields were counted.
In the invasion assay, cells were seeded in matrigel-
coated 6.5 mm Transwell champers (8 μm pore size;
BD Biosciences, San Jose, CA USA). Six hours later, the
cells that had been translocated to lower compartments
of the wells and attached to the lower surface of the
filter were fixed in methanol and stained with crystal-
violet. The stained cells were counted in five indepen-
dent fields in each Transwell.
Immunofluorescence and microscopy
Cells were plated onto 18 mm2 coverslips, fixed in 3% par-
aformaldehyde (PFA) and 2% sucrose for 15 minutes at
room temperature (RT), permeabilized in 20 mM Tris
HCI pH 7.5, 75 mM NaCl, 300 mM sucrose, 3 mM MgCl2
and 0.5% Triton-X-100 for 15 minutes at RT and blocked
with 5% goat serum in phosphate-buffered saline (PBS) for
1 h at RT. Slides were stained with an E-cadherin antibody
(BD Biosciences) at 4°C overnight, washed, incubated with
secondary antibody and images were collected on an
OLYMPUS BX51 microscope equipped with an OLYM-
PUS XM10 camera (OLYMPUS, Center Valley, PA USA).
RNA extraction and real-time PCR
Total RNA was isolated using TriZol reagent (Invitrogen)
and reverse-transcribed to cDNA using a SuperScript™
II reverse transcriptase kit (Invitrogen). Real-Time PCR
was performed using the SyBr green PCR kit (Applied
Biosystems, Grand Island, NY USA). EGFR mRNA levels
were additionally analyzed using TaqMan mRNA assay
according to the manufacturer’s instructions (Applied
Biosystems). All quantitative data were normalized to
GAPDH and actin-b. For microRNAs, real-time PCR was
performed as above using TaqMan microRNA assays
(Applied Biosystems). All microRNA data are expressed
relative to a U6 small nuclear (sn) RNA TaqMan PCR
performed on the same sample. The sequences of the pri-
mers used for qPCR are listed in the Additional file 1,
Table S1.
Immunoblotting and immunoprecipitation
Cells were lysed in RIPA buffer, including protease and
phosphatase inhibitors as previously described [28]. For
separation of cytoplasmic and nuclear fractions, cells
were suspended in a cold buffer containing 10 mM
Hepes pH 7.0, 10 mM KCI, 0.1 mM EDTA, 1 mM DTT
and 0.5 mM PMSF. After 15 minutes’ incubation on ice,
the homogenate was mixed with 10% NP-40 and centri-
fuged for 30 sec. The nuclear pellet was resuspended in a
cold buffer containing 10 mM Hepes-KOH pH 7.9,
400 mM NaCI, 0.1 mM EDTA, 5% glycerol, 1 mM DTT
and 0.5 mM PMSF and the nuclear extract was isolated
by centrifugation. The blots were performed as previously
described [28]. Primary antibodies used in immunoblot-
ting include: ERa, E-cadherin, N-cadherin, cadherin-11,
vimentin, ZEB-1, SIP1, Lamin A/C and Tubulin (Santa
Cruz Biotechnology, Santa Cruz, CA USA), actin-b
(Sigma St. Louis, MO USA), EGFR (Santa Cruz Biotech-
nology, Cell Signaling, Danvers, MA USA), ERb1 (14C8;
GeneTex, Irvine, CA USA), which detects an N-terminal
epitope and recognizes the ERb isoforms derived from
alternative splicing of the last exon, including ERb1 and
an in-house antibody that detects an epitope in ligand
binding domain of ERb1 (amino acids 320 to 527)) [29],
SNAIL (Abcam, Cambridge, MA USA), p-ERK1/2 and
total ERK1/2 (Cell Signaling), c-Cbl (BD Biosciences).
Recombinant ERb1 (Invitrogen) was loaded in SDS-
PAGE gels and used as a positive control. For ubiquityla-
tion analysis, cells were lysed in RIPA buffer containing
protease inhibitor cocktail (Roche, Branchburg, NJ USA).
The lysates were briefly sonicated and cleared by centri-
fugation at 4°C. Supernatants were incubated with anti-
EGFR antibody overnight at 4°C and A/G agarose beads
for 2 h at 4°C. The immunocomplexes were washed three
times, boiled in 2× sample buffer and immunoblotted with
anti-ubiquitin antibody (Santa Cruz Biotechnology). For
the EGFR-c-Cbl co-immunoprecipitations, cells were lysed
in a buffer containing 50 mM Hepes pH 7.4, 150 mM
NaCI, 1 mM EDTA, 1 mM EGTA, 1% Nonidet P-40, 1%
glycerol including protease and phosphatase inhibitors.
Lysates were incubated on ice for 30 minutes without soni-
cation, cleared by centrifugation and the cleared lysates
were subjected to immunoprecipitation as described.
Zebrafish tumor model and generation of fluorescent cells
Animal work was approved by the Institutional Animal
Care and Use Committee (IACUC) at the University of
Houston. Control (Lenti) and ERb1-expressing (ERb1)
MDA-MB-231 cells were stably transfected with either
the pAmCyan vector or the pCMCV-DsRed vector
(Clontech, Mountain View, CA USA). A tumor cell sus-
pension (5 nL) of approximately 300 to 500 cells contain-
ing a mixture of equal numbers of either DsRed-Lenti:
AmCyan-ERb1 cells or AmCyan-Lenti:DsRed-ERb1 cells
were injected into the perivitelline cavity of each 48 h
post-fertilization casper Tg(Flk-1;EGFP) anesthetized
embryo using a pressure injector (Harvard Apparatus,
Holliston, MA USA) and Manipulator (MM33-Right,
Märzhäuser Wetzlar, Wetzlar, Germany). Glass needles
(1.00 mm in diameter, Sutter Instrument Company,
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Novato, CA USA), were used for the microinjection.
Injected embryos were kept at 32°C and were examined
every day for tumor invasion using a fluorescent micro-
scope (OLYMPUS IX51) equipped with an OLYMPUS
XM10 camera. Information for the zebrafish lines is
included in the Additional file 2, Supplementary materi-
als and methods.
Patient information
A tissue microarray consisting of 240 breast cancer sam-
ples was constructed by the Tayside Tissue Bank. Access
to tumor samples was approved by the Tayside Regional
Ethics Committee with written informed consent from
contributing patients. Clinical history and tumor charac-
teristics were available for 238 cases. The clinicopathologi-
cal characteristics of these patients are summarized in the
Additional file 3, Table S2. The majority of the patients
received adjuvant endocrine therapy or combined endo-
crine therapy and chemotherapy, with or without radio-
therapy. Among these patients, 74.7% were ERa-positive,
53.7% were PR-positive and 14.5% were HER2-positive.
Histologically, 192 invasive ductal carcinomas (80.6%), 14
invasive lobular carcinomas (5.8%), 5 tubular carcinomas
(2.1%), 5 mucinous carcinomas (2.1%) and 22 other histo-
logical or mixed types (9.2%) were included.
Antibody validation and immunohistochemistry
The anti-ERb1 antibody (clone PPG5/10, Dako, Carpin-
teria, CA USA), which is specific for the C-terminal amino
acid sequences of ERb1, was used for immunohistochem-
istry (IHC). This antibody was validated by immunocyto-
chemistry. Briefly, H1299 human lung cancer cells were
stably transfected with the pIRES empty vector (Clontech)
or the recombinant pIRES-ERb1 or pIRES-ERb2 plasmids.
Control, ERb1 and ERb2-expressing cells were fixed with
10% formalin. The cell suspension was centrifuged and the
cell pellet was folded in sharkskin filter paper using four
overlapping edges and placed within the base of a tissue
cassette. The cassette was placed in a specimen bucket
with 10% formalin. The formalin-fixed cell material was
embedded in paraffin, cut at 5 μm intervals and used for
H&E staining and IHC.
For immunohistochemistry, formalin-fixed, paraffin-
embedded sections were de-paraffinized with xylene and
rehydrated through a graded alcohol series. For antigen
retrieval, the slides were immersed in 10 mM sodium
citrate buffer (pH 6.0) and maintained at a sub-boiling
temperature for six minutes. The endogenous peroxidase
activity was blocked by incubation in 0.3% hydrogen perox-
ide solution for 20 minutes. The slides were first incubated
with 1% bovine serum albumin (BSA) to block non-specific
staining and then with the primary antibody overnight at
4°C in a humidified chamber. The sections were then pro-
cessed according to the Dako DAB detection kit.
The results of the immunohistochemistry were assessed
by a pathologist (SK) in a blinded fashion. Each specimen
was assigned a score according to the intensity of the
nuclear staining (for ERb1) and cytoplasmic and mem-
brane staining (for E-cadherin) (no staining = 0, weak
staining = 1, moderate staining = 2, strong staining = 3)
and the extent of stained cells (0% = 0, 1 to 24% = 1, 25 to
49% = 2, 50 to 74% = 3, 75 to 100% = 4). The final immu-
noreactive score was determined by multiplying the inten-
sity score with the extent of the score of stained cells,
ranging from 0 (the minimum score) to 12 (the maximum
score). We defined ERb1 expression as low (score 0 to 4),
medium (score 5 to 8) and high (score 9 to 12). For E-cad-
herin, we defined a 0 score as negative and a 1 to 12 as
positive.
Statistical analysis
The correlation between expression of ERb1 and E-cad-
herin, respectively, was determined using Pearson’s corre-
lation test. All statistical tests were two-sided and P-values
less than or equal to 0.05 were considered as statistically
significant. The statistical analyses were performed using
SPSS 20.0 software (SPSS, IBM, Armonk, NY USA).
Results
ERb1 is required for the epithelial breast cancer
phenotype
Basal-like phenotypes are high-grade (grade III), ERa-
negative invasive breast tumors that express EMT markers
and show cadherin switching as a consequence of tumor
de-differentiation [7]. Previous studies have shown a
decline of ERb1 expression from ductal carcinoma in situ
(DCIS) to invasive cancer and an association of the recep-
tor with the repression of mesenchymal characteristics in
invasive prostate cancer [22,30,31]. We hypothesized that
ERb1 regulates EMT in breast cancer and that low ERb1
expression in a proportion of basal-like cancers is asso-
ciated with mesenchymal characteristics and poor clinical
outcome. To test this hypothesis, we stably expressed
ERb1 in the invasive triple-negative breast cancer MDA-
MB-231 and Hs578T cells and compared the expression
levels achieved in these cells with the endogenous expres-
sion of ERs in MCF-7 cells (Additional file 4, Figure S1).
According to recent studies, MDA-MB-231 and Hs578T
cells most resemble the claudin-low breast cancer subtype;
however, as basal-like tumors, they display low expression
of the luminal and HER2 gene clusters and express low
amounts of ERb1 [32]. Induction of ERb1 expression pro-
moted morphological changes in these cells characterized
by the loss of the “fibroblastoid-like” phenotype and
the acquisition of an epithelial-like compact morphology
(Figure 1A, B, upper panel). Furthermore, a more spindle-
shaped morphology was observed when endogenous ERb1
was knocked down with ERb siRNA in Hs578T cells
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Figure 1 ERb1 inhibits invasion and migration in breast cancer cells by regulating EMT. (A) Control (Lenti), ERa- and ERb1-expressing
MDA-MB-231 cells following incubation with EtOH or 17b-estradiol (E2) for 24 h (scale bars, 50 μm). (B) Control (Lenti) and ERb1-expressing
Hs578T cells (upper panel) and Hs578T cells that were transiently transfected with a siRNA targeting luciferase (Control) or a specific ERb siRNA
(siRNA 3#) (lower panel) were photographed (scale bars, 100 μM). (C) Control (Lenti), ERa- and ERb1-expressing MDA-MB-231 cells were
incubated with EtOH or E2 and assessed for invasion by using matrigel-coated Transwell chambers. The cells that were translocated to the lower
surface of the filter were shown (left panel) (scale bars, 500 μm). The graph shows the mean (cell number per field) of three separate
experiments with the standard error of the mean (SEM) and P-value (*) ≤0.05% indicated. (D) Control (Lenti) and ERb1-expressing MDA-MB-231
cells were incubated with E2 for 24 h and assessed for migration using wound-healing assay. The bar graph shows the mean (cells migrated
into the wound) of three separate experiments with SEM and P-value (*) ≤0.05% indicated. (E) E-cadherin protein levels in control (Lenti), ERa-
or ERb1-expressing MDA-MB-231 cells. (F) E-cadherin expression was analyzed by immunoblotting in MDA-MB-231 cells transfected with control
or ERb siRNA (3#) (upper panel) and qPCR in MDA-MB-231 cells transfected with control or three specific ERb siRNAs (lower panel). The graph
indicates the mean of three separate experiments with SEM and P-value (*) ≤0.05%. (G) E-cadherin was visualized by immunofluorescence in
control (Lenti) and ERb1-expressing cells (scale bars, 20 μm).
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(Figure 1B, lower panel). Induction of ERb1 expression
altered the morphology of the MDA-MB-231 and Hs578T
cells in the absence of ligand. The morphology of the
ERb1-expressing MDA-MB-231 cells following treatment
with 17b-estradiol (E2) was similar to that of the untreated
cells (Figure 1A). Consistent with the changes in the mor-
phology, induction of ERb1 expression in MDA-MB-231
cells repressed invasion and migration (Figure 1C, D),
functions characteristic of EMT [33]. Although induction
of ERb1 and ERa expression resulted in a similar activa-
tion of an ERE-luciferase reporter, ERa failed to promote
epithelial morphology and reduce the invasiveness
of MDA-MB-231 cells (Figure 1A, C; Additional file 4,
Figure S1; Additional file 5, Supplementary figure legends).
Similar to the impact on the cellular morphology and
invasiveness, only ERb1 inhibited cadherin switching as
shown by the up-regulation of epithelial E-cadherin in
both MDA-MB-231 and Hs578T cells and down-regula-
tion of the mesenchymal cadherin-11 in MDA-MB-231
and N-cadherin in Hs578T cells (Figures 1E and 2A, B;
Additional file 6 Figure S2A). The positive correlation
between ERb1 and E-cadherin expression was confirmed
by the decrease of E-cadherin mRNA and protein levels
when ERb1 was knocked down in MDA-MB-231 cells
(Figure 1F). In line with the results from the immuno-
blotting analysis, immunofluorescence showed higher
expression of E-cadherin in the cell surface of the ERb1-
expressing cells compared to the control cells (Figure 1G).
This suggests that ERb1 up-regulates the functional form
of E-cadherin that promotes cell-cell adhesion. No altera-
tion in the levels of the mesenchymal marker vimentin
was detected in ERb1-expressing MDA-MB-231 cells sug-
gesting that ERb1 induces cell-cell adhesion in these
cells by primarily regulating the expression of cadherin
(Figure 2B; Additional file 6 Figure S2B).
miR-200 and ZEB1/2 are involved in ERb1-mediated
regulation of E-cadherin
A number of transcription factors (SNAIL, SLUG, TWIST,
SIP-1 and ZEB-1) have been shown to promote EMT in
vitro by acting as transcriptional repressors of E-cadherin
[34,35]. Nuclear translocation of SNAIL has been shown
to repress E-cadherin expression in ERb1 knockdown
prostate cancer cells [22]. Based on these data, we exam-
ined whether SNAIL inhibition is involved in the ERb1-
mediated induction of E-cadherin expression that we
observed in breast cancer cells. Surprisingly, induction of
ERb1 expression in MDA-MB-231 cells neither altered the
expression nor the intracellular localization of SNAIL as
assessed by immunoblotting using cytoplasmic and nuclear
extracts from control and ERb1-expressing cells as well
as immunofluorescence microscopy using a SNAIL Ab
(Additional file 7, Figure S3A, B). Instead, up-regulation of
ERb1 in MDA-MB-231 and Hs578T cells repressed the
expression of the transcriptional repressors of E-cadherin
ZEB-1 and SIP-1 (Figure 2C). Given that recent studies
have reported that the microRNA-200 family and miR-205
regulate EMT by targeting ZEB-1 and SIP-1, we examined
whether the expression of members of the microRNA-200
family and miR-205 were up-regulated prior to repression
of ZEB-1 and SIP-1 expression in ERb1-expressing cells
[16]. Using quantitative real-time PCR we found that the
cluster of miR-200b-200a-429 was up-regulated by more
than 7-fold in the ERb1-expressing MDA-MB-231 and
Hs578T cells (3.5-fold increase only for miR-429 in
Hs578T cells) (Figure 2D; Additional file 8, Figure S4A). In
addition, reduction of endogenous ERb1 expression in
MDA-MB-231 and Hs578T cells by ERb siRNA led to a
decrease in the expression of miR-200a, miR-200b and
miR-429 (Figure 2E; Additional file 8, Figure S4B). In
contrast to the cluster of miR-200b-200a-429, the cluster
miR-200c-141 and the miR-205 were unchanged in ERb1-
expressing MDA-MB-231 cells (Additional file 9, Figure
S5). We also examined how important is the up-regulation
of miR-200a-b-429 for the ERb1-mediated repression of
EMT. We transfected the ERb1-expressing MDA-MB-231
cells with inhibitors of miR-200a, miR-200b and miR-429
and assessed the level of functional knockdown of
miR200a-b-429 by a reporter assay, in which the comple-
mentary sequence of miR200a-b-429 was introduced in
the 3’ UTR of a luciferase reporter gene. Transfection of
the cells with miR200a-b-429 inhibitors resulted in a more
than two-fold increase in luciferase activity compared with
the negative control inhibitor suggesting that a greater than
50% inhibition of the miR200a-b-429 function had been
achieved by the miR200a-b-429 inhibitors (Figure 2F). Inhi-
bition of miR200a-b-429 partially reversed the ERb1-
mediated epithelial phenotype and caused a 50% reduction
in the expression of E-cadherin (Figure 2F). These data
strengthen the role of ERb1 in regulating EMT and suggest
a mechanism through which the receptor may regulate
E-cadherin expression.
ERb1 inhibits EMT by repressing EGFR signaling
EGFR that is overexpressed in MDA-MB-231 and Hs578T
cells has been associated with poor survival in basal-like
breast cancers (Additional file 10, Figure S6). Overexpres-
sion of EGFR is known to promote migration in breast
cancer cells [36,37]. Activation of EGFR following ligand
binding results in phosphorylation and activation of extra-
cellular-signal-regulated kinases (ERKs) [38]. Activation of
ERK2 has recently been shown to promote EMT by indu-
cing the expression of the transcriptional repressors of
E-cadherin ZEB-1 and SIP-1 [17,18]. Given the repression
of ZEB-1 and SIP-1 expression observed in ERb1-expres-
sing MDA-MB-231 and Hs578T cells, we examined
whether ERb1 inhibits EMT by down-regulating EGFR
signaling. Induction of ERb1 expression caused a strong
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Figure 2 ERb1 induces the expression of E-cadherin by up-regulating members of the microRNA 200 family and repressing the
expression of ZEB-1 and SIP-1. (A) E-cadherin mRNA levels in control (Lenti), ERa- and ERb1-expressing MDA-MB-231 cells following
incubation with or without E2 for 24 h. The graph shows the mean of three separate experiments with SEM and P-value (*) ≤0.05% indicated.
(B) Left panel: protein levels of EMT markers in control (Lenti), ERa- and ERb1-expressing MDA-MB-231 cells following incubation with or without
E2 for 24 h. Right panel: E- and N-cadherin protein levels in control (Lenti) and ERb1-expressing Hs578T cells. (C) ZEB-1 and SIP-1 protein levels
in control (Lenti), ERa- and ERb1-expressing MDA-MB-231 cells (upper panel) and in control and ERb1-expressing Hs578T cells (lower panel).
(D) Control, ERa- and ERb1-expressing MDA-MB-231 cells were analyzed for miR-200a, miR-200b and miR-429 expression by qPCR. The graphs
show data as fold change compared with the untreated Lenti cells (mean of three separate experiments with SEM and P-value (*) ≤0.05%
indicated). (E) MDA-MB-231 cells were transiently transfected with control or ERb siRNA (3#) and analyzed for miR-200a, miR-200b and miR-429
expression by qPCR. The graphs show the mean of three separate experiments with SEM and P-value (*) ≤0.05% indicated. (F) ERb1-expressing
MDA-MB-231 cells were transfected with inhibitors of miR-200a, miR-200b and miR-429 or a negative control inhibitor. Cells were photographed
and analyzed for E-cadherin expression by qPCR (scale bars, 50 μm). The level of functional knockdown of miR-200a-b-429 was examined by a
miR-200a-b-429-regulated reporter assay. The graphs show the mean of three separate experiments with SEM and P-value (*) ≤0.05% indicated.
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reduction in the EGFR protein levels in MDA-MB-231
and Hs578T cells and decreased the phosphorylation of
ERK1/2 as assessed by immunoblotting using an ERK1/2
phospho-specific antibody (Figure 3A, B). Furthermore,
reduction of endogenous ERb1 expression in MDA-MB-
231 cells led to up-regulation of EGFR (Figure 3C). Analy-
sis of EGFR mRNA by qPCR showed the same levels in
control and ERb1-expressing cells as well as in cells where
ERb1 had been knocked down, suggesting that ERb1 does
not regulate the transcription of EGFR gene (Additional
file 6, Figure S2C). To test whether the ERb1-EGFR inter-
action is a critical regulator of EMT in basal-like breast
cancer cells, we treated the ERb1-expressing cells with
EGF or the EMT inducer TGF-b1 for 24 h. For the same
purpose, we stably transfected the ERb1-expressing MDA-
MB-231 cells with an empty vector or a plasmid that
encodes wild-type EGFR. As expected, treatment of the
cells with EGF restored the phosphorylation of ERK1/2,
decreased the cell-cell contact observed in the ERb1-
expressing cells and abolished the ERb1-mediated up-
regulation of miR-200a-200b-429 and the increased levels
of E-cadherin (Figure 3D-F, 3G). In contrast, treatment of
the cells with TGF-b1, for the same time period as for
EGF, failed to reverse the ERb1-induced phenotype in
MDA-MB-231 cells (Figure 3D, F, G). As in the case of
EGF treatment, EGFR overexpression induced a more
fibroblastoid morphology in ERb1-expressing cells, which
was accompanied by down-regulation of E-cadherin
(Figure 3H).
ERb1 induces degradation of EGFR by enhancing the
EGFR-c-Cbl interaction
Given that ERb1 altered only the protein but not the
mRNA levels of EGFR, we set out to investigate whether
ERb1 regulates EGFR at a post-transcriptional level. Spe-
cifically, we hypothesized that ERb1 induces degradation
of the EGFR protein. EGFR degradation occurs through a
process that includes ubiquitylation of the receptor,
accelerated endocytosis and degradation by proteasomal
and lysosomal hydrolases [39]. In chase experiments,
expression of ERb1 reduced the half-life of EGFR sug-
gesting that EGFR protein turnover was enhanced by
ERb1 (Figure 4A). Treatment of the cells with the protea-
some inhibitor MG-132 inhibited the ERb1-dependent
reduction in EGFR protein abundance (Figure 4B) con-
firming that EGFR down-regulation in ERb1-expressing
cells was due to increased degradation. Given that ubi-
quitylation is an important step in the degradation of
EGFR, we carried out ubiquitylation assays to test
whether ERb1 induces ubiquitylation of EGFR. Interest-
ingly, the levels of the ubiquitylated EGFR were dramati-
cally increased in ERb1-expressing MDA-MB-231 and
Hs578T cells (Figure 4C). Furthermore, the ubiquitylated
EGFR was decreased when ERb1 was knocked down in
MDA-MB-231 cells (Figure 4D). Given that ubiquityla-
tion of the activated EGFR is mediated by members of
the Cbl family of RING domain E3 ubiquitin ligases,
including the c-Cbl [40], we examined whether ERb1
promotes ubiquitylation of EGFR by inducing its associa-
tion with c-Cbl. In control MDA-MB-231 cells, immuno-
precipitation of EGFR under nondenaturing conditions
showed a rapid but transient recruitment of c-Cbl to
EGFR with a barely detectable c-Cbl-EGFR association at
45 minutes following EGF induction. ERb1-expressing
MDA-MB-231 cells showed enhanced and more sus-
tained c-Cbl-EGFR association with high amounts of
c-Cbl recruited to EGFR even at 45 minutes following
EGF induction (Figure 4E). These results strengthen our
hypothesis that ERb1 down-regulates EGFR by inducing
its degradation.
ERb1 inhibits invasion of breast cancer cells in vivo
To study the role of ERb1 in regulating early events of the
metastatic cascade, we used a zebrafish tumor model in
which the Tg(flk1:EGFP)/casper zebrafish embryos were
implanted with the highly metastatic human MDA-MB-231
cells. The Tg(flk1:EGFP)/casper embryos lack pigmentation
and express green fluorescent protein (GFP) in the vascular
system for direct visualization of vascular development [41].
Both control (Lenti) and ERb1-expressing MDA-MB-231
cells were stably transfected with either DsRed or AmCyan
fluorescent proteins. A mixture of either control-DsRed and
ERb1-AmCyan cells or control-AmCyan and ERb1-DsRed
cells were injected into the perivitelline cavity at 48 hours
post-fertilization (hpf), at which time the immune system of
the fish is not yet developed. The zebrafish were first
imaged 3 h after implantation (Figure 5A, B, upper panels).
Invasion and dissemination of DsRed and AmCyan cells
were monitored daily in zebrafish. At five days post-injec-
tion (dpi), both DsRed and AmCyan MDA-MB-231 control
cells had significantly disseminated away from the primary
injection site, including the head and the tail regions,
whereas ERb1-expressing MD-MB-231 cells labeled with
either DsRed or AmCyan remained at the primary site
(Figure 5A-D). Out of 45 embryos that were injected with
both control and ERb1-expressing cells, 27 embryos had
disseminated control cells, and only 2 embryos had dissemi-
nated control and ERb1-expressing cells. However, in these
two zebrafish, the ratio of control:ERb1 disseminated cells
was more than 8:1 (Figure 5E; Additional file 11, Figure S7).
Our results show that the difference in metastatic potential
between the control and the ERb1-expressing cells is due to
their different capacity to invade and disseminate.
ERb1 and E-cadherin levels are positively correlated in
breast cancers
Since ERb1 induces the expression of E-cadherin in
breast cancer cells, we next examined the correlation of
Thomas et al. Breast Cancer Research 2012, 14:R148
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Figure 3 EGFR promotes EMT and its down-regulation is involved in ERb1-induced E-cadherin expression. (A) EGFR, total ERK1/2 and
phospho-ERK1/2 levels in control (Lenti), ERa- and ERb1-expressing MDA-MB-231 cells following incubation with or without E2 for 24 h. (B)
EGFR protein levels in control (Lenti) and ERb1-expressing Hs578T cells. (C) EGFR protein levels in MDA-MB-231 cells transiently transfected with
control or ERb siRNA (3#). (D) ERb1-expressing MDA-MB-231 cells were incubated in absence or presence of 5 ng/ml TGF-b1 or 10 ng/ml EGF
for 24 h and photographed (scale bars, 50 μm). (E) ERb1-expressing MDA-MB-231 cells were incubated in absence or presence of 10 ng/ml EGF
for 24 h and analyzed for the expression of EGFR, total ERK1/2 and phospho-ERK1/2 by immunoblotting. Note that the decreased EGFR levels
following EGF treatment is due to increased degradation. (F) miR-200a, miR-200b and miR-429 levels in control (Lenti) and ERb1-expressing
MDA-MB-231 cells following incubation with 5 ng/ml TGF-b1 or 10 ng/ml EGF for 24 h. The graph shows the data as fold change compared
with the untreated Lenti cells (mean of three separate experiments (± SEM) with P-value (*) ≤0.05%). (G) E-cadherin mRNA and protein levels in
ERb1-expressing MDA-MB-231 cells following incubation with 5 ng/ml TGF-b1 or 10 ng/ml EGF for 24 h. The graph shows the mean of three
separate experiments with SEM and P-value (*) ≤0.05% indicated. (H) ERb1-expressing MDA-MB-231 cells were stably co-transfected with an
empty pBABE vector (ERb1:pBABE cells) or the pBABE-EGFR plasmid (ERb1:EGFR cells), photographed and analyzed for EGFR, E-cadherin and ERb1
expression by immunoblotting (scale bars, 50 μm).
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ERb1 and E-cadherin protein levels in breast tumor
samples. We utilized a tissue microarray of 240 primary
untreated and unselected breast cancers. Clinical history
and tumor characteristics (tumor type, age, size, grade,
lymph node status, ERa, PR and HER2 status) that were
available for 238 cases are summarized in Additional file
3, Table S2. ERb1 and E-cadherin protein levels were
determined by IHC using an ERb1 specific antibody
(PPG5/10; DAKO). The specificity of the ERb1 antibody
was confirmed by immunocytochemistry (Additional file
12 Figure S8A, B). A total of 32 samples were excluded
from the analysis due to the absence of tumor or
presence of benign tumor in the core. We carried out
Pearson’s correlation analysis with the information of
ERb1 and E-cadherin expression from the 208 cancers.
Pearson’s correlation analysis showed a strong positive
correlation between ERb1 and E-cadherin expressions
(P = 3.41e-4) (Figure 6A).
To better understand the correlation between ERb1 and
E-cadherin, we divided the breast cancer samples into
three groups based on ERb1 levels defined by their expres-
sion scores and studied the difference of E-cadherin
expression among the three groups. The expression of
E-cadherin in each group was represented by its median
Figure 4 ERb1 induces ubiquitylation and degradation of EGFR. (A) Control (Lenti) and ERb1-expressing MDA-MB-231 cells were incubated
in the presence of 100 μM cycloheximide and 10 ng/ml EGF for the indicated times and analyzed for EGFR expression by immunoblotting.
Treatment with EGF induces phosphorylation of EGFR and this accounts for the retarded electrophoretic mobility of EGFR at times 0.5 to 2.
Lower panel: the graph represents the quantification of EGFR protein abundance from three independent experiments with SEM and P-value (*)
≤0.05% indicated. (B) Control (Lenti) and ERb1-expressing MDA-MB-231 cells were incubated in absence or presence of 1 μM MG-132 for 6 h
and analyzed for EGFR expression by immunoblotting. Lower panel: the bar graph represents the quantification of EGFR protein levels with SEM
and P-value (*) ≤0.05% indicated. (C) Control (Lenti) and ERb1-expressing MDA-MB-231 and Hs578T cells were incubated in the presence of 10
ng/ml EGF for 20 minutes. Lysates were immunoprecipitated with anti-EGFR antibody, followed by immunoblotting with the indicated
antibodies. The bottom panel is the input control of cell lysates. (D) MDA-MB-231 cells were transiently transfected with control or ERb siRNA
(3#). 72 h after the transfection, cells were incubated with 10 ng/ml EGF for 20 minutes and analyzed as described in C. (E) Control (Lenti) and
ERb1-expressing MDA-MB-231 cells were serum starved, challenged with 10 ng/ml EGF for the indicated times and lysed under nondenaturing
conditions. EGFR immunoprecipitates were probed with antibodies against EGFR and c-Cbl. The bottom panel is the input control of cell lysates.
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score (Figure 6C) or positive percentage (Figure 6D). As
shown in Figure 6C, the median scores of E-cadherin in
tumors expressing low levels of ERb1 were significantly
smaller than in those with higher ERb1 levels. Similarly,
the positive percentage analysis for E-cadherin showed a
positive correlation with ERb1 levels (Figure 6D). These
results are consistent with our findings that ERb1 up-regu-
lates E-cadherin in breast cancer cell lines.
Discussion
Although basal-like breast cancers in general are associated
with relatively poor prognosis, they are heterogeneous,
including diverse subgroups in terms of chemotherapy
response and risk of developing distant metastases [2,6,7].
Interestingly, ERb1 positivity has recently been associated
with better survival in triple-negative cancers that were
treated with tamoxifen and inversely correlated with the
expression of EGFR, an important marker in the immuno-
histochemical identification of basal-like cancers [24,25,36].
One process that has been attributed to primary tumor
metastasis is EMT. Here we examined whether ERb1
through regulating EMT can influence invasion and metas-
tasis in basal-like cancers. ERb1 repressed the mesenchy-
mal spindle-shaped morphology of the MDA-MB-231 and
Hs578T cells and enhanced cell-cell contact. ERb1 altered
the morphology of these cells in the absence of ligand.
Figure 5 ERb1 inhibits MDA-MB-231 tumor cell invasion, dissemination and micrometastasis in vivo. Control (Lenti) and ERb1-expressing MDA-
MB-231 cells were stably transfected with pAmCyan or pCMCV-DsRed vector. A tumor cell suspension containing equal numbers of either DsRed-Lenti:
AmCyan-ERb1 cells (A) or AmCyan-Lenti:DsRed-ERb1 cells (B) were injected into perivitelline space of 48 hpf embryos and tumor cell invasion and
dissemination were detected using fluorescent microscopy at 5 dpi. The upper panels show the zebrafish 3 hpi. Arrowheads indicate disseminated
tumor cells (Scale bar, 500 μm). (C and D) High magnification micrographs of A and B, respectively (scale bar, 100 μm). (E) Table showing the number of
zebrafish injected with either DsRed-Lenti:AmCyan-ERb1 or AmCyan-Lenti:DsRed-ERb1 MDA-MB-231 cells, the number of zebrafish with disseminated
human tumor cells and the number of the zebrafish with disseminated cells in different regions of the body. (F) DsRed-Lenti, AmCyan-Lenti, DsRed-
ERb1 and AmCyan-ERb1 MDA-MB-231 cells were analyzed for ERb1 expression by immunoblotting. (BF, blue filter; RF, red filter; GF, green filter).
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Figure 6 ERb1 levels positively correlate with E-cadherin in breast cancers. (A) Pearson’s correlation of ERb1 expression with expression of
E-cadherin. N equals the number of patients for whom data were available. (B) Representative images of ERb1 and E-cadherin expression in two
serial sections of the same tumor from two cases. Scale bars represent 200 μM. (C) ERb1 and E-cadherin were box-plotted in the 208 breast
cancer patients. The patients were divided into three groups based on ERb1 expression scores in the tumors, representing low, medium and
high expression of ERb1. Any outliers were marked with a circle and extreme cases with an asterisk. Data were analyzed using one-way ANOVA
test with Games-Howell’s correction. (D) The percentage of E-cadherin-positive tumors was analyzed in the three groups of patients as described
in C. Data were analyzed using Pearson’s c2 test. (E) Proposed mechanism for how ERb1 regulates EMT and influences invasion in breast cancer.
EGFR promotes EMT in basal cells by activating ERK1/2, which in turn, by inducing the expression of ZEB1/2, results in the down-regulation of E-
cadherin. This process requires repression of the expression of members of miR-200 family. By inducing the degradation of EGFR, ERb1 sustains
ERK1/2 inactive, up-regulates miR200a-b and miR-429, down-regulates ZEB1/2 and induces the expression of E-cadherin.
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This is in agreement with our previous data showing
increased transcriptional activity following expression of
ERb1 in MDA-MB-231 cells in the absence of ERb ago-
nists. The increased transcriptional activity in the absence
of ligand was correlated with the phosphorylation of ERb1
at ser-87 [28]. As a result of the changes in the morphol-
ogy, ERb1 inhibited migration and reduced the invasive-
ness of MDA-MB-231 cells. When control and ERb1-
expressing cells were injected into zebrafish embryos, only
the control cells disseminated to distant sites suggesting
that ERb1 functions as a crucial anti-invasive factor. Given
that expression of EMT markers and cadherin switching
have been reported to correlate with the basal-like pheno-
types in in vitro model systems and in specimens from
patients [7], we examined whether ERb1 inhibits invasion
and migration by regulating EMT in cells with basal char-
acteristics. ERb1 was found to induce the expression of E-
cadherin by inhibiting its transcriptional repressors ZEB1/2
and up-regulating the miR-200a, miR-200b and miR-429,
which correlate with the epithelial breast cancer phenotype
(Figure 6E).
ERK2 has recently been shown to affect the ZEB1/2
regulatory pathway of E-cadherin expression in human
mammary cells [17,18]. ERK1/2 are activated by diverse
pathways including that initiated by EGFR [38]. Overex-
pression of EGFR promotes migration and invasion of
basal cells and its expression correlates with poor survi-
val in basal-like cancers [36,37]. Since ERb1 was found
to inhibit EMT by down-regulating the ZEB1/2 pathway
in basal-like cells, we tested whether repression of EGFR
and ERK1/2 signaling are involved in ERb1-mediated
up-regulation of E-cadherin and the subsequent inhibi-
tion of cell migration and invasion. Indeed, ERb1
induced a decrease in EGFR protein levels without alter-
ing the transcription of the EGFR gene followed by
down-regulation of the phosphorylated ERK1/2 forms.
Induction of EGFR signaling in ERb1-expressing cells
through up-regulation of EGFR or treatment of the cells
with EGF reversed the ERb1-dependent epithelial phe-
notype, suggesting that EGFR is a critical factor in the
ERb1-mediated regulation of EMT.
Given that inhibition of transcription was not involved
in ERb1-mediated down-regulation of EGFR, we exam-
ined whether ERb1 promotes degradation of the tyrosine
kinase receptor. EGFR degradation is a complex process
that involves ubiquitylation of the activated receptor by
the E3 enzyme Cbl and subsequent proteolysis by pro-
teosomal and lysosomal hydrolases [39]. ERb1 was
found to induce ubiquitylation and degradation of EGFR
by enhancing the EGFR-c-Cbl association. Ubiquityla-
tion is an important process of a negative regulatory cir-
cuit that terminates EGFR signaling by targeting the
receptor for degradation [42]. Our data show for first
time that ERb1, by inducing these negative feedback
pathways, is likely to exert a role of EGFR inhibitor and
tumor suppressor function.
Interestingly, it has recently been shown that ERb
decreases the expression of insulin-like growth factor II-
mRNA binding protein 3 (IMP-3) by repressing EGFR
transcription in MDA-MB-231 cells [43]. In our study,
the transcription of EGFR was not altered when ERb1
was expressed or knocked down in MDA-MB-231 and
Hs578T basal-like cells. Instead, as mentioned above,
ERb1 promotes degradation of EGFR by inducing its
ubiquitylation in both MDA-MB-231 and Hs578T cells.
By examining 208 clinical breast cancer specimens, we
found that the expression of ERb1 was significantly asso-
ciated with the expression of E-cadherin. This correlation
has not previously been reported. However, since the dis-
covery of ERb, it has been shown that the association of
ERb to other clinicopathological indicators is likely to be
divergent in different breast cancer cohorts analyzed by
IHC using different ERb antibodies. The tumor cohort
examined in our study included a different number of
HER2-positive (14.5%) and probably triple-negative breast
cancers compared with the cohorts utilized in some of the
recent studies that examined large number of samples
with well-validated antibodies (HER2-positive, Honma
et al. 2008: 5.25% and Novelli et al. 2008: 31.9%) [24,25,
44,45]. Such differences in the characteristics of the clini-
cal cancer samples as well as differences in the specificity
of the ERb antibodies used in these studies, may explain
why the correlation between ERb1 and E-cadherin expres-
sion has not been previously observed. This positive
ERb1-E-cadherin association is consistent with the ERb1-
mediated up-regulation of E-cadherin observed in breast
cancer cells. It is possible that there are some limitations
in the relevance of these results since the level of ERb1-
expression achieved in our cells may not reflect the levels
of expression seen in clinical samples. Despite these limita-
tions, taken together, our results propose a role for ERb1
in up-regulating E-cadherin in breast cancer cells. This
suggests that the low ERb1 levels may be the primary
cause of low E-cadherin expression and induction of EMT
in some breast cancers. Since EMT correlates with a
group of basal-like breast cancers that often develop
metastases in distant sites [7], ERb1 may play a crucial
role in repressing invasive behavior and inhibiting metas-
tasis in this subset of breast cancers. Our data show that
ERb1 impedes EMT and influences invasion by down-
regulating EGFR, which is expressed in basal-like cancers.
These results strengthen the possibility that ERb1 can help
to identify patients with basal-like cancer with lower risk
to develop metastasis.
Conclusions
Basal-like breast cancers that show unfavorable prog-
nosis and often develop distant metastases are associated
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with EMT. Our findings indicate that ERb1 inhibits
EMT and reduces the invasiveness of basal-like breast
cancer cells by up-regulating the epithelial marker E-
cadherin. ERb1 induces the expression of E-cadherin by
down-regulating EGFR, an oncogenic factor that is
expressed in basal-like cancers. ERb1 was found to ter-
minate EGFR signaling by targeting the receptor for
degradation. Our data support the notion that ERb1 can
serve as a clinical marker to identify patients with basal-
like cancer that have lower risk to develop metastasis.
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